**Benefits of a Balance Exercise Assist Robot in the Cardiac Rehabilitation of Older Adults with Cardiovascular Disease: A Preliminary Study**

Kakeru Hashimoto 1, Akihiro Hirashiki 2, Kenichi Ozaki 1, Koki Kawamura 1, Junpei Sugioka 1, Shunya Tanioku 1, Kenji Sato 1, Ikue Ueda 1, Naoki Itoh 1, Kenichiro Nomoto 2, Manabu Kokubo 2, Atsuya Shimizu 2 and Izumi Kondo 1

**Abstract:** We examined whether adding robot-supported balance exercises to cardiac rehabilitation improves the ability to balance in older adults with cardiovascular disease (CVD). We conducted a prospective study in 52 older adults who had been hospitalized for worsening CVD. Once weekly for four months, for a total of sixteen sessions as outpatients, the subjects used a Balance Exercise Assist Robot (BEAR) to perform balance exercises and an ergometer for aerobic exercises. Participants’ mean age was 76.9 ± 6.8 years (range, 65–95 years). They were divided into two groups based on their level of physical functioning: one group showed significant improvements in gait speed (before, 1.06 ± 0.33 m/s; after, 1.23 ± 0.30 m/s; p < 0.001), Short Physical Performance Battery score (before, 9.10 ± 2.25; after, 10.88 ± 1.79; p < 0.001), timed up-and-go (before, 11.11 ± 5.07 s; after, 9.45 ± 3.45 s; p < 0.001), and knee extension (before, 26.97 ± 11.78 kgf; after, 30.13 ± 13.04 kgf; p = 0.001). Cardiac rehabilitation including exercises using BEAR improved physical functioning and the ability to balance in older adults with CVD. Frail and prefrail patients improved, whereas robust ones did not change.

**Keywords:** cardiovascular disease; balance exercise assist robot; older adults; frailty; cardiac rehabilitation; robotic rehabilitation

1. Introduction

The number of patients with cardiovascular disease (CVD) increases with age [1]. Older adults with CVD often have multiple comorbidities, including reduced exercise capacity, decreased physical and cognitive functions, and depression [2]. In addition, they frequently have problems typical of older adults in general, including frailty [3] and sarcopenia [4]. Frailty encompasses physical, social, and cognitive/depression aspects that contribute to both adverse cardiovascular outcomes and non-cardiovascular mortality [5]. These various problems decrease the life expectancy of older adults with CVD [6,7]. Few data are available regarding balance function in people with CVD [8]. These patients often have skeletal muscle disorders [9] that contribute to poor balance function [10]. In addition, the combination of frailty and sarcopenia increases the risk of falls [11,12]. In particular, the risk of femoral fracture after a fall is greater in patients with heart failure [13]. Therefore, it is important to focus on improving balance function and decreasing falls in both community-dwelling older adults and those with CVD.

In this context, measures are needed to improve the balance capacity of CVD patients and reduce their risk of falls. Exercise therapy including balance exercises is one effective
method of preventing falls [14]. In addition, many CVD patients undergo cardiac rehabilitation (CR); traditionally, CR programs are based on exercise therapy including aerobic exercise and resistance training. However, conventional CR programs do not improve participants’ balance function [15]. As the number of older patients has increased, balance training, flexibility exercises, and secondary preventive interventions have been added to conventional CR programs [16,17]. These modified CR protocols improve not only exercise tolerance but also balance function [18]. For these reasons, we feel that balance training strategies need to be optimized for older adults with CVD.

Several recent studies have shown that exercises using a Balance Exercise Assist Robot (BEAR) improve balance function [19–22]. Compared with traditional exercises only, those incorporating a BEAR improved dynamic balance among community-dwelling frail and prefrail older adults [19]. In addition, exercises using a BEAR have increased balance function in patients with central nervous system disorders [20] and in older adults with hip fractures [21]. These reports suggest that balance practice involving a BEAR might also improve the balance function of older adults with CVD. Therefore, the aim of the current study was to examine whether adding robotic balance exercises to CR improved the balance ability of older adults with CVD.

2. Materials and Methods

2.1. Study Population

This prospective interventional study involved patients who were at least 65 years old and who had been hospitalized for worsening CVD (Department of Cardiology, National Center for Geriatrics and Gerontology, Obu, Japan) between August 2019 and December 2021. Participants performed a cardiopulmonary exercise test; underwent laboratory measurements, echocardiography, and a physical function evaluation; and completed questionnaires, including the Fall Efficacy Scale-International (FES-I), Geriatric Depression Scale (GDS), and Mini Nutritional Assessment-Short Form (MNA-SF).

Standard echocardiographic measurements were obtained in accordance with the current guidelines of the European Association of Cardiovascular Imaging [23]. All echocardiographic examinations were performed by 4 senior sonographers who are accredited members of the Japan Society of Ultrasonics in Medicine and registered medical sonographers. Transthoracic echocardiograms were performed in the left lateral decubitus or supine position. All patients underwent M-mode, 2-dimensional, pulsed, and color tissue Doppler echocardiography from a phased-array electronic ultrasound system using Vivid 7 (GE Healthcare, Wauwatosa, WI, USA) or iE33 (Philips Healthcare, Eindhoven, The Netherlands) software. The left ventricular ejection fraction was measured according to the modified Simpson’s method. The peak flow velocities at the mitral level during rapid filling (E) and atrial contraction (A), the E/A ratio, and the deceleration time were calculated from the pulsed Doppler echocardiography data. We recorded the tissue Doppler imaging wave of the mitral annulus from the septal side of the apical 4-chamber view and analyzed the early diastolic filling velocity (E’). The operators making the echocardiographic evaluations were blinded to the patients’ clinical status. These assessments were performed just before discharge, after the patients had been medically stabilized.

The inclusion criteria were structural heart disease consisting of coronary artery disease (having experienced angina pectoris or myocardial infarction, with a history of revascularization procedures); symptomatic heart failure (non-ischemic cardiomyopathy, ischemia, tachycardia, bradycardia, valvular, or hypertension); and others. Non-ischemic cardiomyopathies were defined as ventricular myocardial abnormalities in the absence of coronary artery disease or valvular, pericardial, or congenital heart disease [24]. Tachycardia and bradycardia included atrial, supraventricular, and ventricular arrhythmias; sick sinus syndrome; and atrioventricular block in the absence of structural heart disease. Valvular heart disease was diagnosed on the basis of hemodynamic or echocardiographic findings or a history of valvular or congenital cardiac surgery according to the American College of Cardiology-American Heart Association guideline [25]. Hypertension was defined as a
systolic blood pressure $\geq 140$ mmHg, a diastolic blood pressure $\geq 90$ mmHg, or a history of treatment for hypertension. Included as “others” were aortic disease, peripheral artery disease, and other vascular diseases. Worsening heart failure was defined as a clinical syndrome comprising symptoms and/or signs due to structural and/or functional cardiac abnormality and accompanied by elevated natriuretic peptide levels and/or objective evidence of pulmonary or systemic congestion [26].

Exclusion criteria were severe respiratory dysfunction (i.e., patients receiving long-term oxygen therapy for respiratory disease), liver dysfunction (Child–Pugh score class C), stroke, renal dysfunction (reduced glomerular filtration rate and albuminuria category G5), malignant tumors with a prognosis of less than 1 year, criteria corresponding to the CR contraindications in the Guidelines for Rehabilitation in Patients with Cardiovascular Disease of the Japanese Circulation Society [27], cognitive inability to understand how to operate the BEAR, and visual or hearing impairments that could interfere with playing the games.

The study protocol complied with the Declaration of Helsinki, and written informed consent was obtained from each subject. The Ethics Review Board of Nagoya University approved the study (approval no. 2020).

2.2. Clinical Characteristics

Frailty was defined according to the revised Japanese version of the Cardiovascular Health Study (J-CHS) criteria [28]. J-CHS assesses 5 components: weight loss, physical activity, tiredness, muscle weakness, and gait speed. Frailty is defined as the presence of signs or symptoms associated with at least 3 of the 5 components, prefrailty as showing signs or symptoms consistent with 1 or 2 components, and robustness as having no features attributable to any of the components.

2.3. BEAR

The BEAR (Toyota Motor Corporation, Aichi, Japan) used in this study had 2 wheels, an in-wheel motor controlled by an inverted pendulum system, and a foot plate on either side (Figure 1 and Supplementary Video S1). The BEAR moves backward and forward and left and right according to shifts in the operator’s center of gravity. Balance exercise that promotes movement in these 4 directions is achieved by playing 3 games, which focus on different skills: (A) a skiing game, which requires left–right movement; (B) a rodeo game, which requires keeping the robot stationary against irregular disturbances; and (C) a tennis game, which involves forward–backward movement (Figure 1). The level of difficulty was adjusted to suit the individual, and the users performed the repetitive movements automatically [21].

Figure 1. Balance Exercise Assist Robot (BEAR). The BEAR moves backward–forward and left–right according to shifts in the operator’s center of gravity. These movements can be incorporated into balance exercises by playing 3 games: (A) a skiing game, which involves using left–right movement; (B) a rodeo game, which requires responses to disturbance stimuli from the BEAR; and (C) a tennis game, which responds to forward–backward movement.
To ensure safety during the exercises, we prepared a 2.4 m × 2.0 m space in the exercise room for participants' exclusive use. In addition, participants wore a safety harness to limit fall risk; no lifting force was applied to reduce weight-bearing.

2.4. CR Program

Participants performed balance exercises by using the BEAR and aerobic exercises by using an ergometer. The intervention was performed on an outpatient basis once weekly for four months, with sixteen sessions in total. Each balance practice session using the BEAR comprised 12 episodes: 4 rounds each of the 3 games, with each round being 1.5 min long. Aerobic exercise was performed for 15 min under loading as determined from the results of cardiopulmonary exercise testing. The load was increased gradually according to the subjective exercise intensity: when the Borg score was less than 12, the load was increased slightly; when the Borg score was 15 or higher, we reduced the number of games played or shortened the duration of aerobic exercise.

2.5. Measurements

Peak oxygen uptake (peak VO\textsubscript{2}), 10 m gait test (gait speed), Short Physical Performance Battery (SPPB) score, timed up-and-go (TUG) test, muscle strength of knee extension (knee extension), FES—I, GDS, and MNA—SF were assessed just before discharge after the patients had been medically stabilized and at the end of the 4-month intervention period.

2.5.1. Peak Oxygen Uptake

Each patient underwent cardiopulmonary exercise testing (AE-310S, NIHON KOHDEN, Tokyo, Japan) on a cycle ergometer at a progressively increasing work rate to maximal tolerance. The test protocol was conducted according to the recommendations of the American Thoracic Society and American College of Chest Physicians [29]. Gas-exchange data were obtained breath by breath, and peak VO\textsubscript{2} was determined as the highest oxygen value recorded during the test.

2.5.2. The 10 m Gait Test

Participants were instructed to walk twice in a 16 m direction at a comfortable pace [30]. The time taken to cover 10 m along the walkway was measured, and the gait speed was calculated from the measured time.

2.5.3. SPPB

The SPPB evaluates lower limb function [31] through its 3 components: balance tests (closed leg standing, semi-tandem standing, tandem standing), walking time, and standing from a seated position. Its reliability, validity, and feasibility in older adults have been reported [32]. The maximum score is 12 points: the higher the score, the better the physical function.

2.5.4. TUG Test

The TUG test measures the time required for a participant to stand up from an armchair, walk 3 m, turn, return to the chair, and sit down again [33].

2.5.5. Muscle Strength of Knee Extension

The strength of knee extension was measured by using a handheld dynamometer (μ-tas F-1; Anima, Tokyo, Japan). Knee extension was tested while the participant was seated, with the knee and hip flexed at 90° [34]. Each strength test was performed twice, and the best result was recorded.

2.5.6. FES-I

The FES-I was developed by the Prevention of Falls Network Europe [35]. FES-I is a 16-question evaluation that assesses anxiety about falling in daily life or social activities.
Respondents classify their anxiety about falling as “no concern” (1 point), “somewhat concerned” (2 points), “fairly concerned” (3 points), or “very concerned” (4 points). The points for the 16 questions are summed (16 to 64 points in total): the higher the score, the greater the fear of falling.

2.5.7. GDS

The GDS is a 15-item indicator of depression that is used in Japan [36]. The maximum score is 15 points, and higher scores represent more severe depression. A score of 10 or more indicates the presence of depression.

2.5.8. MNA-SF

The MNA-SF consists of 6 items. MNA-SF considers food intake, weight loss, and physical and psychological stress over the last 3 months, as well as body mass index [37]. MNA-SF scoring identifies 3 nutrition levels: 0 through 7 points, malnourished; 8 through 11 points, at risk of malnutrition; and 12 through 14 points, normal nutrition status.

2.6. Statistical Analysis

Continuous variables are reported as means and standard deviations (mean ± SD). Categorical data are reported as the percentage of all subjects. Parameters obtained just before discharge after the patients had been medically stabilized were compared with those at the end of the 4-month intervention period by using paired t-tests and Mann–Whitney U-tests. Normality of data distribution was confirmed by using the Shapiro–Wilk test. All statistical analyses were performed by using SPSS version 27.0 (IBM, New York, NY, USA), with significance defined as \( p < 0.05 \).

3. Results

3.1. Clinical Characteristics

Figure 2 is a flow chart that describes how we derived the study population. The demographic and baseline clinical characteristics of the 52 patients enrolled (Table 1) were obtained once the patients were clinically stable in terms of their CVD. The average age of the study population was 76.9 ± 6.8 years; 53.8% of subjects were male; 88.4% of subjects were patients with worsening heart failure; the brain natriuretic protein concentration was 164.0 ± 190.9 pg/mL; the left ventricular ejection fraction was 57.7% ± 12.0%; and 28.8% of patients were frail. In terms of underlying diseases, 28.8% of participants had ischemic heart disease, and 23.1% had tachycardia-induced heart failure, such as atrial fibrillation or atrial flutter, or an implantable cardioverter defibrillator; 82.7% of subjects had heart failure with a preserved ejection fraction.
3. Results

3.1. Clinical Characteristics

Figure 2 is a flow chart that describes how we derived the study population. The demographic and baseline clinical characteristics of the 52 patients enrolled (Table 1) were obtained once the patients were clinically stable in terms of their CVD. The average age of the study population was 76.9 ± 6.8 years; 53.8% of subjects were male; 88.4% of subjects were patients with worsening heart failure; the brain natriuretic protein concentration was 164.0 ± 190.9 pg/mL; the left ventricular ejection fraction was 57.7% ± 12.0%; and 28.8% of patients were frail. In terms of underlying diseases, 28.8% of participants had ischemic heart disease, and 23.1% had tachycardia-induced heart failure, such as atrial fibrillation or atrial flutter, or an implantable cardioverter defibrillator; 82.7% of subjects had heart failure with a preserved ejection fraction.

CR: Cardiac rehabilitation

Figure 2. Flow chart of participant inclusion. Of the 127 patients admitted to the cardiology department of our hospital between August 2019 and December 2019, 52 were included in the study. CR, cardiac rehabilitation.

3.2. Effect of CR including BEAR Exercises

Table 2 shows the results of a comparison of each parameter just before discharge after the patients had been medically stabilized (baseline) and at the end of the 4-month intervention period (after 4 months). Overall, participants achieved significant improvements in gait speed ($p < 0.001$), SPPB score ($p < 0.001$), TUG time ($p < 0.001$), and knee extension ($p = 0.001$; Table 2 and Figure 3) after completing CR including BEAR exercises. In particular, the participants who were prefrail at baseline showed significant improvements in gait speed ($p < 0.001$), TUG time ($p = 0.008$), and knee extension ($p = 0.003$). After completing CR including BEAR exercises, frail participants showed significant improvements in gait speed ($p < 0.001$), SPPB score ($p = 0.004$), TUG time ($p = 0.004$), and knee extension ($p = 0.042$). Robust patients showed no difference in any of the parameters after CR including BEAR exercises. No adverse events occurred.
Table 1. Clinical characteristics of study participants (n = 52).

| Characteristic                                      | Value                        |
|-----------------------------------------------------|------------------------------|
| Age (years)                                         | 76.9 ± 6.8                   |
| Sex (male, %)                                       | 53.8                         |
| Body mass index (kg/m²)                             | 22.7 ± 3.3                   |
| **Coronary risk factor**                            |                              |
| Diabetes mellitus (n, %)                            | 8 (15.4)                     |
| Dyslipidemia (n, %)                                 | 17 (32.4)                    |
| Tobacco users (n, %)                                | 1 (1.9)                      |
| **Underlying diseases**                             |                              |
| Worsening heart failure (n, %)                      | 46 (88.4)                    |
| Non-ischemic cardiomyopathy (n, %)                  | 2 (3.8)                      |
| Ischemic heart disease (n, %)                       | 15 (28.8)                    |
| Tachycardia-induced (n, %)                          | 12 (23.1)                    |
| Atrial fibrillation/Atrial flutter (n, %)           | 11 (21.2)                    |
| Implantable cardioverter defibrillator (n, %)       | 1 (1.9)                      |
| Bradycardia; Implanted pacemaker (n, %)             | 5 (7.7)                      |
| Valvular (n, %)                                     | 4 (7.7)                      |
| Post TAVI (n, %)                                    | 3 (5.9)                      |
| Post MVR (n, %)                                     | 1 (1.9)                      |
| Hypertension (n, %)                                 | 4 (7.7)                      |
| Others (n, %)                                       | 4 (9.6)                      |
| Aortic disease (n, %)                               | 2 (3.8)                      |
| Atrial septal defect (n, %)                         | 2 (3.8)                      |
| Post PCI/CABG (n, %)                                | 6 (11.6)                     |
| **Medication**                                      |                              |
| Diuretics (n, %)                                    | 20 (38.5)                    |
| Tolvaptan (n, %)                                    | 8 (15.4)                     |
| ACE-I/ARB (n, %)                                    | 23 (44.2)                    |
| β blocker (n, %)                                    | 24 (46.2)                    |
| Spironolactone (n, %)                               | 6 (21.1)                     |
| Anticoagulant (n, %)                                | 25 (48.1)                    |
| Antiplatelet agent (n, %)                           | 25 (48.1)                    |
| **Laboratory data**                                 |                              |
| BNP (pg/mL)                                         | 164.0 ± 190.9                |
| Hemoglobin (mg/dL)                                  | 12.8 ± 1.7                   |
| Total protein (g/dL)                                | 6.8 ± 0.6                    |
| Albumin (g/dL)                                      | 3.9 ± 0.5                    |
| Total cholesterol (mg/dL)                           | 173.8 ± 37.1                 |
| eGFR (mL/min/1.73 m²)                               | 63.4 ± 17.0                  |
| **Echocardiography**                                |                              |
| Left atrial dimension (mm)                          | 40.6 ± 9.3                   |
| LVEF (%)                                            | 57.7 ± 12.0                  |
| < 40% (n, %)                                        | 5 (9.6)                      |
| 41–50% (n, %)                                       | 4 (7.7)                      |
| E/e'                                                | 14.3 ± 5.4                   |
| **CPX**                                             |                              |
| Respiratory exchange ratio                          | 1.2 ± 0.1                    |
| Maximal workload (W)                                | 58.6 ± 26.1                  |
| Predicted peak VO₂ (%)                              | 62.7 ± 17.5                  |
| **Frailty**                                         |                              |
| J-CHS (robust/prefrail/frail) (%)                    | 7.7/63.5/28.8                |
| **Others**                                          |                              |
| Depressive symptoms (n, %)                          | 4 (7.7)                      |
| Educational level (years)                           | 11.8 ± 2.4                   |

ACE-I/ARB, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker; BNP, brain natriuretic peptide; CABG, coronary artery bypass graft; E/e’, ratio of transmitral Doppler early filling velocity to tissue Doppler early diastolic mitral annular velocity; eGFR, estimated glomerular filtration rate; J-CHS, Japanese version of the Cardiovascular Health Study criteria; LVEF, left ventricular ejection fraction; MVR, mitral valve reconstruction; PCI, percutaneous coronary intervention; TAVI, transcatheter aortic valve implantation. Depressive symptoms: the number of participants with GDS of 10 points or more where applicable, data are given as means ± SD.
Table 2. BEAR effects.

|                          | Baseline    | After 4 Months | p     |
|--------------------------|-------------|----------------|-------|
| **All participants (n = 52)** |             |                |       |
| Peak VO\textsubscript{2} (mL/min/kg) | 14.09 ± 3.79 | 14.53 ± 3.88 | 0.222 |
| Gait speed (m/s)         | 1.06 ± 0.33 | 1.23 ± 0.30   | <0.001|
| SPPB (points)           | 10.02 ± 2.25 | 10.88 ± 1.79 | <0.001|
| TUG (s)                 | 11.11 ± 5.07 | 9.45 ± 3.45   | <0.001|
| Knee extension (kgf)     | 26.97 ± 11.78 | 30.13 ± 13.04 | 0.001 |
| FES-I (points)          | 22.91 ± 8.16 | 21.45 ± 7.17  | 0.139 |
| GDS (points)            | 2.90 ± 3.38  | 2.21 ± 2.76   | 0.057 |
| MNA-SF (points)         | 9.48 ± 2.37  | 12.03 ± 2.05  | <0.001|
| LVEF (%)                | 59.16 ± 9.88 | 58.58 ± 9.93  | 0.366 |
| E/'                     | 14.03 ± 4.32 | 13.77 ± 4.73  | 0.638 |
| BNP (pg/mL)             | 29.79 ± 10.26 | 26.71 ± 9.92  | 0.264 |

**Pre-frail participants (n = 33)**

|                          | Baseline    | After 4 Months | p     |
|--------------------------|-------------|----------------|-------|
| Peak VO\textsubscript{2} (mL/min/kg) | 15.08 ± 3.68 | 15.59 ± 3.86 | 0.231 |
| Gait speed (m/s)         | 1.14 ± 0.29 | 1.29 ± 0.29   | <0.001|
| SPPB (points)           | 10.72 ± 1.67 | 11.14 ± 1.66 | 0.090 |
| TUG (s)                 | 9.54 ± 2.86 | 8.73 ± 2.69  | 0.008 |
| Knee extension (kgf)     | 27.89 ± 11.88 | 32.33 ± 13.31 | 0.003 |
| FES-I (points)          | 19.56 ± 3.97 | 19.48 ± 3.69 | 0.899 |
| GDS (points)            | 1.50 ± 1.46 | 1.27 ± 1.20  | 0.394 |
| MNA-SF (points)         | 9.78 ± 2.65 | 11.83 ± 2.23 | 0.005 |
| LVEF (%)                | 60.76 ± 8.83 | 60.04 ± 7.01 | 0.412 |
| E/'                     | 12.87 ± 3.94 | 12.98 ± 3.39 | 0.839 |
| BNP (pg/mL)             | 113.72 ± 136.58 | 142.00 ± 170.79 | 0.254 |

**Frail participants (n = 15)**

|                          | Baseline    | After 4 Months | p     |
|--------------------------|-------------|----------------|-------|
| Peak VO\textsubscript{2} (mL/min/kg) | 12.64 ± 3.64 | 12.49 ± 3.37 | 0.875 |
| Gait speed (m/s)         | 0.79 ± 0.25 | 1.05 ± 0.27   | <0.001|
| SPPB (points)           | 8.47 ± 2.72 | 10.20 ± 2.14  | 0.004 |
| TUG (s)                 | 15.09 ± 6.80 | 11.46 ± 4.35 | 0.004 |
| Knee extension (kgf)     | 18.73 ± 8.29 | 21.32 ± 9.75 | 0.042 |
| FES-I (points)          | 29.79 ± 10.26 | 26.71 ± 9.92 | 0.264 |
| GDS (points)            | 6.07 ± 4.25 | 4.33 ± 3.92  | 0.092 |
| MNA-SF (points)         | 8.92 ± 2.19 | 12.33 ± 1.78 | <0.001|
| LVEF (%)                | 54.86 ± 12.13 | 54.12 ± 14.34 | 0.499 |
| E/'                     | 17.15 ± 3.98 | 16.05 ± 7.21 | 0.538 |
| BNP (pg/mL)             | 284.50 ± 239.78 | 203.50 ± 171.94 | 0.264 |

BNP, brain natriuretic peptide; E/' , ratio of transmitial Doppler early filling velocity to tissue Doppler early diastolic mitral annular velocity; FES-I, Fall Efficacy Scale—international; GDS, Geriatric Depression Scale; knee extension, muscle strength of knee extension; LVEF, left ventricular ejection fraction; MNA-SF, Mini Nutritional Assessment—Short Form; peak VO\textsubscript{2}, peak oxygen uptake; SPPB, Short Physical Performance Battery; TUG, timed up-and-go. Baseline: just before discharge, after patients had been medically stabilized. After 4 months: 4 months after beginning CR intervention including BEAR exercises.

Table 3 shows the comparison between parameters at baseline and after 4 months of CR including BEAR exercises in male and female participants: gait speed (male; p = 0.001, female; p < 0.001), SPPB (male; p = 0.003, female; p = 0.029), TUG (male; p = 0.002, female; p = 0.010), and knee extension (male; p = 0.007, female; p = 0.048). Overall, both sexes showed similar results after participating in CR and BEAR exercises for 4 months.
Figure 3. Intervention effect of CR including BEAR exercises (all patients). Changes in 10 m gait test (gait speed), Short Physical Performance Battery score (SPPB), timed up-and-go (TUG) test, muscle strength of knee extension (knee extension), and fear of falling (Fall Efficacy Scale—International, FES-I).
Table 3. BEAR effects in participants according to sex.

|                        | Men (n = 28) | Women (n = 24) | p     |
|------------------------|--------------|----------------|-------|
|                        | Baseline     | After 4 Months |       |
| Peak VO₂ (mL/min/kg)   | 14.46 ± 4.14 | 14.99 ± 4.26   | 0.148 |
| Gait speed (m/s)       | 1.11 ± 0.33  | 1.25 ± 0.28    | 0.001 |
| SPPB (points)          | 10.31 ± 1.72 | 11.08 ± 1.83   | 0.003 |
| TUG (s)                | 9.98 ± 4.30  | 8.76 ± 3.07    | 0.002 |
| Knee extension (kgf)   | 33.96 ± 11.20| 37.52 ± 12.43  | 0.007 |
| FES-I (points)         | 22.00 ± 6.78 | 20.46 ± 5.52   | 0.141 |
| GDS (points)           | 2.36 ± 2.86  | 1.68 ± 1.68    | 0.263 |
| MNA-SF (points)        | 10.18 ± 1.98 | 12.00 ± 2.06   | 0.012 |
| LVEF (%)               | 56.37 ± 11.36| 55.24 ± 10.71  | 0.230 |
| E/e'                   | 12.90 ± 4.19 | 12.73 ± 3.99   | 0.813 |
| BNP (pg/mL)            | 156.69 ± 216.24| 164.19 ± 199.62| 0.814 |

All abbreviations are as in Table 2.

4. Discussion

To assess whether adding a recently developed device, the BEAR, to CR improves the balance ability of older adults with CVD, we conducted a prospective study in 52 adults (age ≥ 65 years) who were admitted to our hospital for worsening CVD. After discharge, participants used a BEAR to perform balance exercises and an ergometer to perform aerobic exercises on an outpatient basis once weekly for four months (i.e., 16 sessions in total). We found that CR intervention involving a BEAR improved gait speed, SPPB score, TUG time, and knee extension—but not peak VO₂ or FES-I—in older adults with CVD. In addition, no adverse events, such as fatal arrhythmia, syncope, worsening heart failure, or acute coronary syndrome, occurred while participants performed BEAR exercises; one participant discontinued BEAR exercises owing to knee pain.

Several robotic assist devices have been shown to be effective components of exercise therapy protocols. Exercise therapy with a robotic walking support device improved the exercise ability and quality of life of patients with heart failure [38]. An exoskeleton-type robot was safe to use in patients with heart failure, and the subjects showed a high interest in using this tool [39]. To our knowledge, our current study is the first to report on exercise therapy using a BEAR in CR protocols for older adults with CVD.

In a previous study, the use of a BEAR improved gait speed, TUG time, and the muscle strength of knee extension among community-dwelling frail and prefrail older adults [19]. We obtained similar results with our current study population. Furthermore, the reported Minimal Clinically Important Difference (MCID) for gait speed is 0.05 m/s [40], for SPPB is 0.5 points [40], for TUG time is 1.2 s [41], and for muscle strength of knee extension is 3.3 kgf [42]. In the current study, improvements in these various physical function parameters after 4 months of CR including BEAR exercises were equivalent, or superior, to the MCID. Additional beneficial features of a BEAR as a mechanism for improving balance function include: (1) high similarity between BEAR game tasks and ankle and hip posture strategies; (2) appropriate and automatic adjustment of game difficulty; and (3) the ability of suitably difficult games to cue an operator to actively move their center of gravity and thus refine posture strategies [19].

Our current study represents a first attempt at incorporating a BEAR into CR intervention for CVD patients, who we thought might benefit by learning posture strategies through BEAR exercises. Previous studies assessing balance training were diverse in terms of exercise type and duration, and the reported effects were likewise varied [43,44]. Therefore, we consider that one advantage of a BEAR is that the difficulty level is tailored automatically and appropriately to each subject, so that essentially everyone can practice balancing correctly [20]. In our sub-analyses, the prefrail and frail groups—but not robust participants—showed significantly improved balance after 4 months. This finding suggests that frail CVD patients might particularly benefit from CR programs that incorporate BEAR exercises to improve balance function.
In several previous studies, CR improved peak VO$_2$ in CVD patients [45], as did exercise therapy in frail older adults [46]. However, adding BEAR exercises to CR did not alter peak VO$_2$ in our current study, similar to the lack of effect of CR on peak VO$_2$ in frail older adults with CVD [47]; the underlying reason remains unknown. In the present study, 92% of participants were prefrail or frail, and whether the degree of frailty or cardiac dysfunction influenced our results is unclear. In addition, age is a reported determinant of improvement in exercise tolerance [48]; the average age of our participants exceeded 75 years and might therefore have influenced our current results. In contrast, after using BEAR for 4 months, participants’ nutritional status (i.e., MNA-SF score) was significantly improved, and their depression (i.e., GDS score) showed a trend toward improvement. These results suggest that, even without increases in peak VO$_2$, CR using BEAR might mitigate frailty overall.

In the current study, 88.4% of participants had worsening heart failure, and those with heart failure and a preserved ejection fraction accounted for 83.7%. CR has been reported to improve the prognosis of frail patients with heart failure with preserved ejection fraction [49]. Our data might be generalizable to all cardiovascular system diseases for which CR is appropriate. The success of CR is highly dependent on long-term patient compliance [17], and determining the appropriate exercise intensity is important for the rehabilitation of patients with CVD because it influences compliance as well as the effectiveness and safety of the incorporated exercise training [50]. How best to determine the appropriate intensity of both aerobic and resistance exercises for patients with CVD warrants urgent attention. Furthermore, neither the optimal intervention period nor the optimal exercise intensity for exercise therapy involving a BEAR has been determined, and these issues merit further investigation.

Although FES-I scores did not improve after the 4-month BEAR protocol, none of our participants had a fall-induced fracture during the intervention period. The average FES-I score for our participants was 22.91 ± 8.16 points, compared with reported cut-off values of 24 points for community-dwelling elderly patients [51], 23 points for diabetic female patients [52], and 28 points for stroke patients [53]. In addition, the average FES-I score for our study population was lower than that for older adults with hip fractures (32.0 ± 11.3 points) [21]. Compared with their peers, the subjects in our current study may have had less fear of falling, and performing BEAR exercises may have further helped these older adults with CVD avoid fractures due to falls. These ideas should be explored in a future study involving more patients.

Limitations of the current study include its small number of participants (fewer than 50% of patients initially identified were enrolled in the study), the lack of a control group, use of a single facility, and lack of a follow-up survey of cardiovascular events. We considered comparing our current results with data from a historical population that had already performed conventional CR and could serve as a control group, but we were unable to do so because of lack of sufficient data and appropriately similar patients. Owing to the small number of participants, we were unable to verify the effects of age, sex, type or severity of disease, and comorbidities on our findings. Moreover, owing to the lack of a control group, the effect of balance exercises using a BEAR could not be separated from those due to other components of the CR intervention. However, we can attest that using a BEAR is safe in older adults with CVD. In the future, we need to investigate whether CR including BEAR exercises reduces the risks of falls, fractures, readmissions, and early deaths in this population.

5. Conclusions

CR including BEAR exercises improved physical functioning—including balance—in older adults with CVD. Despite the small number of subjects, robust subjects showed no changes, whereas those who presented as frail or prefrail improved in a number of parameters. The effects of CR including BEAR exercises on these patients and their prognoses should be verified through randomized controlled trials and follow-up surveys.
Supplementary Materials: The following supporting information can be downloaded at: https://susy.mdpi.com/user/manuscripts/displayFile/3b55f4c75f73a324f64edc5b5b30a9f/supplementary (accessed on 17 April 2022).

Author Contributions: Conceptualization: K.H., A.H., K.O., K.K., K.S., N.I. and I.K.; methodology: K.H., A.H., K.K., K.S. and I.K.; formal analysis: K.H. and K.K.; investigation: K.H., J.S., S.T. and I.U.; resources: A.H., K.O., K.N., M.K. and A.S.; data curation: A.H., K.K. and J.S.; writing—original draft preparation: K.H.; writing—review and editing, A.H., N.I. and I.K.; visualization: K.H. and A.H.; supervision: A.H., A.S. and I.K.; project administration: I.K. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study protocol complied with the Declaration of Helsinki, and written informed consent was obtained from each subject. The Ethics Review Board of Nagoya University approved the study (approval no. 2020, date of approval 1 April 2021).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Not applicable.

Acknowledgments: We thank the staff members of the National Center for Geriatrics and Gerontology (Obu, Japan), particularly Shigeharu Tsuzuki, Moeka Isomura, Katsunori Hara, Hideki Yanagisawa, Koharu Oya (physical therapists), and Kimiko Hori (physiological technician).

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Ministry of Health. Statistics and Information Department. Vital Statistics. Available online: https://www.mhlw.go.jp/toukei/list/10-20.html (accessed on 15 February 2022).

2. Ahluwalia, S.C.; Gross, C.P.; Chaudhry, S.I.; Leo-Summers, L.; Van Ness, P.H.; Fried, T.R. Change in comorbidity prevalence with advancing age among persons with heart failure. J. Gen. Intern. Med. 2011, 26, 1145–1151. [CrossRef]

3. Chung, K.; Wilkinson, C.; Veerasamy, M.; Kunadian, V. Frailty Scores and Their Utility in Older Patients with Cardiovascular Disease. Intens. Cardiol. 2021, 16, e05. [CrossRef] [PubMed]

4. Bekfani, T.; Pellicori, P.; Morris, D.A.; Ebner, N.; Valentova, M.; Steinbeck, L.; Wachter, R.; Elsner, S.; Sliziuik, V.; Schefol, J.C.; et al. Sarcopenia in patients with heart failure with preserved ejection fraction: Impact on muscle strength, exercise capacity and quality of life. Int. J. Cardiol. 2016, 222, 41–46. [CrossRef] [PubMed]

5. Richter, D.; Guasti, L.; Walker, D.; Lambrinou, E.; Lions, C.; Abreu, A.; Savelieva, I.; Fumagalli, S.; Bo, M.; Roca, B.; et al. Frailty in cardiology: Definition, assessment and clinical implications for general cardiology. A consensus document of the Council for Cardiology Practice (CCP), Association for Acute Cardiovascular Care (ACVC), Association of Cardiovascular Nursing and Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases (VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO), Working Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology, WG Thrombosis, of the European Society of Cardiology, European Primary Care Cardiology Society (EPCCS). Eur. J. Prev. Cardiol. 2022, 29, 216–227. [CrossRef] [PubMed]

6. Veronese, N.; Cereda, E.; Stubbs, B.; Solmi, M.; Luchini, C.; Manzato, E.; Sergi, G.; Manu, P.; Harris, T.; Fontana, L.; et al. Risk of cardiovascular disease morbidity and mortality in frail and pre-frail older adults: Results from a meta-analysis and exploratory meta-regression analysis. Ageing Res. Rev. 2017, 35, 63–73. [CrossRef] [PubMed]

7. Kamiya, N.H.K.; Matsuzawa, R.; Nozaki, K.; Tanaka, S.; Ichinosawa, Y.; Maekawa, S.; Noda, C.; Yamaoka-Tojo, M.; Matsunaga, A.; Masuda, T.; et al. Sarcopenia: Prevalence and Prognostic Implications in Elderly Patients with Cardiovascular Disease. JSM Clin. Rep. 2017, 2, 1–13. [CrossRef]

8. Yamamoto, A.M.S.; Ishidal, T.; Misawa, K.; Yamazaki, S.; Higuchi, S.; Ohira, M. Exercise-Based Cardiac Rehabilitation for Elderly Patients with Coronary Artery Disease. JSM Phys. Med. Rehabil. 2017, 1, 1003.

9. Supervia, M.; Medina-Inojosa, J.R.; Perez-Terzic, C.M.; Sharma, S.; Goel, K.; Douglas, K.V.; Salz, K.; Thomas, R.J. Impact of Musculoskeletal Limitations on Cardiac Rehabilitation Participation. Front. Cardiovasc. Med. 2021, 8, 688483. [CrossRef]

10. Cooper, C.; Dere, W.; Evans, W.; Kanis, J.A.; Rizzoli, R.; Sayer, A.A.; Sieber, C.C.; Kaufman, J.M.; van Kan, G.A.; Boonen, S.; et al. Frailty and sarcopenia: Definitions and outcome parameters. Osteoporos. Int. 2012, 23, 1839–1848. [CrossRef]

11. Chen, K.W.; Chang, S.F.; Lin, P.L. Frailty as a Predictor of Future Fracture in Older Adults: A Systematic Review and Meta-Analysis. Worldviews Evid. Based Nurs. 2017, 14, 282–293. [CrossRef]

12. Landi, F.; Lipperoti, R.; Russo, A.; Giovannini, S.; Tosato, M.; Capoluongo, E.; Bernabei, R.; Onder, G. Sarcopenia as a risk factor for falls in elderly individuals: Results from the iSIRENTE study. Clin. Nutr. 2012, 31, 652–658. [CrossRef] [PubMed]

13. van Diepen, S.; Majumdar, S.R.; Bakal, J.A.; McAlister, F.A.; Ezekowitz, J.A. Heart failure is a risk factor for orthopedic fracture: A population-based analysis of 16,294 patients. Circulation 2008, 118, 1946–1952. [CrossRef] [PubMed]
14. de Labra, C.; Guimaraes-Pinheiro, C.; Maseda, A.; Lorenzo, T.; Millan-Calenti, J.C. Effects of physical exercise interventions in frail older adults: A systematic review of randomized controlled trials. *BMC Geriatr.* 2015, 15, 154. [CrossRef] [PubMed]

15. Segev, D.; Hellerstein, D.; Carasso, R.; Dunskey, A. The effect of a stability and coordination training programme on balance in older adults with cardiovascular disease: A randomised exploratory study. *Eur. J. Cardiovasc. Nurs.* 2019, 18, 736–743. [CrossRef]

16. Ambrosetti, M.; Abreu, A.; Corra, U.; Davos, C.H.; Hansen, D.; Frederix, I.; Illiou, M.C.; Pedretti, R.F.; Schmid, J.P.; Vgorito, C.; et al. Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. *Eur. J. Prev. Cardiol.* 2020, 28, 460–495. [CrossRef]

17. Abreu, A.; Frederix, I.; Hendale, P.; Janssen, A.; Doherty, P.; Piepoli, M.F.; Voller, H.; Secondary, P.; Davos, C.H. Standardization and quality improvement of secondary prevention through cardiovascular rehabilitation programmes in Europe: The avenue towards EAPC accreditation programme: A position statement of the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology (EAPC). *Eur. J. Prev. Cardiol.* 2020, 28, 496–509. [CrossRef]

18. Lutz, A.H.; Delligatti, A.; Allsup, K.; Afilalo, J.; Forman, D.E. Cardiac Rehabilitation Is Associated with Improved Physical Function in Frail Older Adults with Cardiovascular Disease. *J. Cardiopulm. Rehabil. Prevl. Prent.* 2020, 40, 310–318. [CrossRef]

19. Ozaki, K.; Kondo, I.; Hirano, S.; Kagaya, H.; Saitoh, E.; Osawa, A.; Fujinori, Y. Training with a balance exercise assist robot is more effective than conventional training for frail older adults. *Geriatr. Gerontol. Int.* 2017, 17, 1982–1990. [CrossRef]

20. Ozaki, K.; Kagaya, H.; Hirano, S.; Kondo, I.; Tanabe, S.; Ito, N.; Saitoh, S.; Fuwa, T.; Murakami, R. Preliminary trial of postural strategy training using a personal transport assistance robot for patients with central nervous system disorder. *Arch. Phys. Med. Rehabil.* 2013, 94, 59–66. [CrossRef]

21. Takano, E.; Ozaki, K.; Satoh, K.; Kawamura, K.; Malais, M.; Kondo, I. Effects of a Balance Exercise Assist Robot on Older Patients with Hip Fracture: A Preliminary Study. *J. Med. Biol. Eng.* 2020, 40, 783–789. [CrossRef]

22. Inoue, S.; Otaké, Y.; Kumagai, M.; Sugawara, M.; Mori, N.; Kondo, E. Effects of Balance Exercise Assist Robot training for patients with hemiparetic stroke: A randomized controlled trial. *J. Neuroeng. Rehabil.* 2022, 19, 12. [CrossRef]

23. Lang, R.M.; Badano, L.P.; Mor-Avi, V.; Afilalo, J.; Armstrong, A.; Ernande, L.; Flachskampf, F.A.; Foster, E.; Goldstein, S.A.; Kuznetsova, T.; et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur. Heart J. Cardiovasc. Imaging* 2015, 16, 233–270. [CrossRef] [PubMed]

24. Weintraub, R.G.; Semsarian, C.; Macdonald, P. Dilated cardiomyopathy. *Lancet* 2017, 390, 400–414. [CrossRef]

25. Nishimura, R.A.; Otto, C.M.; Bonow, R.O.; Carabello, B.A.; Erwin, J.P., 3rd; Guyton, R.A.; Gara, P.T.; Ruiz, C.E.; Skubas, N.J.; Soraja, P.; et al. 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 2014, 129, e521–e643. [CrossRef] [PubMed]

26. Bozkurt, B.; Coats, A.J.S.; Tsutsui, H.; Abdelhamid C.M.; Adamopoulos, S.; Albert, N.; Anker, S.D.; Atherton, J.; Bohm, M.; Butler, J.; et al. Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. *Eur. J. Heart Fail.* 2021, 23, 352–380. [CrossRef] [PubMed]

27. JCS Joint Working Group. Guidelines for rehabilitation in patients with cardiovascular disease (JCS 2012). *Circ. J.* 2014, 78, 2022–2093. [CrossRef] [PubMed]

28. Satake, S.; Arai, H. The revised Japanese version of the Cardiovascular Health Study criteria (revised J-CHS criteria). *Geriatr. Gerontol. Int.* 2020, 20, 992–993. [CrossRef]

29. Ross, R.M. ATS/ACCP statement on cardiopulmonary exercise testing. *Am. J. Respir. Crit. Care Med.* 2003, 167, 1451. [CrossRef]

30. Hong, H.-J.; Kim, Y.-M. Effect of Rhythmic Movement Program to Improve Walking Ability for Elderly Patients with Stroke. *Indian J. Sci. Technol.* 2016, 9, 1–6. [CrossRef]

31. Guralnik, J.M.; Simonsick, E.M.; Ferrucci, L.; Glynn, R.J.; Berkman, L.F.; Blazer, D.G.; Scherr, P.A.; Wallace, R.B. A short physical performance battery assessing lower extremity function: Association with self-reported disability and prediction of mortality and nursing home admission. *J. Gerontol.* 1994, 49, M85–M94. [CrossRef]

32. Mijnarends, D.M.; Meijers, J.M.; Halfens, R.J.; ter Borg, S.; Luiking, Y.C.; Verlaan, S.; Schoberer, D.; Cruz Jentoft, A.J.; van Loon, L.J.; Schols, J.M. Validity and reliability of tools to measure muscle mass, strength, and physical performance in community-dwelling older people: A systematic review. *J. Am. Med. Dir. Assoc.* 2013, 14, 170–178. [CrossRef]

33. Podsiadlo, D.; Richardson, S. The timed Up & Go: A test of basic functional mobility for frail elderly persons. *J. Am. Geriatr. Soc.* 1991, 39, 142–148. [CrossRef] [PubMed]

34. Bohannon, R.W. Hand-held dynamometry; stability of muscle strength over multiple measurements. *Clin. Biomech.* 1987, 2, 74–77. [CrossRef]

35. Yardley, L.; Beyer, N.; Hauer, K.; Kempen, G.; Piot-Ziegler, C.; Todd, C. Development and initial validation of the Falls Efficacy Scale-International (FES-I). *Age Ageing* 2005, 34, 614–619. [CrossRef]

36. Sugishita, K.; Sugishita, M.; Hemmi, I.; Asada, T.; Tanigawa, T. A Validity and Reliability Study of the Japanese Version of the Geriatric Depression Scale 15 (GDS-15-J). *Clin. Gerontol.* 2017, 40, 233–240. [CrossRef] [PubMed]
37. Ranhoff, A.H.; Gjøen, A.U.; Mowó, M. Screening for malnutrition in elderly acute medical patients: The usefulness of MNA-SF. *J. Nutr. Health Aging* 2005, 9, 221–225.

38. Schoenrath, F.; Markendorf, S.; Braunclien, A.E.; Frank, M.; Wilhelm, M.J.; Saleh, L.; Rien, R.; Schmied, C.M.; Falk, V. Robot-assisted training for heart failure patients—A small pilot study. *Acta Cardiol.* 2015, 70, 665–671. [CrossRef] [PubMed]

39. Just, I.A.; Fries, D.; Loewe, S.; Falk, V.; Cesarovic, N.; Edelmann, F.; Feuerstein, A.; Haufe, F.L.; Xiloyannis, M.; Rien, R.; et al. Movement therapy in advanced heart failure assisted by a lightweight wearable robot: A feasibility pilot study. *ESC Heart Fail.* 2022, 9, 1643–1650. [CrossRef]

40. Perera, S.; Mody, S.H.; Woodman, R.C.; Studenski, S.A. Meaningful change and responsiveness in common physical performance measures in older adults. *J. Am. Geriatr. Soc.* 2006, 54, 743–749. [CrossRef]

41. Wright, A.A.; Cook, C.E.; Baxter, G.D.; Dockerty, J.D.; Abbott, J.H. A comparison of 3 methodological approaches to defining major clinically important improvement of 4 performance measures in patients with hip osteoarthritis. *J. Orthop. Sports Phys. Ther.* 2011, 41, 319–327. [CrossRef]

42. Iwakura, M.; Okura, K.; Kubota, M.; Sugawara, K.; Kawagoshi, A.; Takahashi, H.; Shioya, T. Estimation of minimal clinically important difference for quadriceps and inspiratory muscle strength in older outpatients with chronic obstructive pulmonary disease: A prospective cohort study. *Phys. Ther. Res.* 2021, 24, 35–42. [CrossRef] [PubMed]

43. Sun, M.; Min, L.; Xu, N.; Huang, L.; Li, X. The Effect of Exercise Intervention on Reducing the Fall Risk in Older Adults: A Meta-Analysis of Randomized Controlled Trials. *Int. J. Environ. Res. Public Health* 2021, 18, 12562. [CrossRef] [PubMed]

44. Kim, Y.; Vakula, M.N.; Bolton, D.A.E.; Dakin, C.J.; Thompson, B.J.; Slocum, T.A.; Teramoto, M.; Bressel, E. Which Exercise Interventions Can Most Effectively Improve Reactive Balance in Older Adults? A Systematic Review and Network Meta-Analysis. *Front. Aging Neurosci.* 2021, 13, 764826. [CrossRef]

45. Gonçalves, C.; Raimundo, A.; Abreu, A.; Bravo, J. Exercise Intensity in Patients with Cardiovascular Diseases: Systematic Review with Meta-Analysis. *Int. J. Environ. Res. Public Health* 2021, 18, 3574. [CrossRef]

46. Binder, E.F.; Schechtman, K.B.; Ehsani, A.A.; Steger-May, K.; Brown, M.; Sinacore, D.R.; Yarasheski, K.E.; Holloszy, J.O. Effects of cardiac rehabilitation on physiologic function and exercise capacity in elderly cardiovascular patients with frailty. *J. Cardiol.* 2021, 77, 424–431. [CrossRef] [PubMed]

47. Ushijima, A.; Morita, N.; Hama, T.; Yamamoto, A.; Yoshimachi, F.; Ikari, Y.; Kobayashi, Y. Effects of cardiac rehabilitation on physical function and exercise capacity in elderly cardiovascular patients with frailty. *J. Cardiol.* 2021, 77, 424–431. [CrossRef] [PubMed]

48. Bianchi, S.; Maloberti, A.; Peretti, A.; Garatti, L.; Palazzini, M.; Occhi, L.; Bassi, I.; Sioli, S.; Biolcati, M.; Giani, V.; et al. Determinants of Functional Improvement After Cardiac Rehabilitation in Acute Coronary Syndrome. *High. Blood Press. Cardiovasc. Prev.* 2021, 28, 579–587. [CrossRef]

49. Kamiya, K.; Sato, Y.; Takahashi, T.; Tsuchihashi-Makaya, M.; Kotooka, N.; Ikegame, T.; Takura, T.; Yamamoto, T.; Nagayama, M.; Goto, Y.; et al. Multidisciplinary Cardiac Rehabilitation and Long-Term Prognosis in Patients with Heart Failure. *Circ. Heart Fail.* 2020, 13, e006798. [CrossRef]

50. Hansen, D.; Abreu, A.; Ambrosetti, M.; Cornelissen, V.; Gevaert, A.; Kemps, H.; Laukkenen, J.A.; Pedretti, R.; Simonenko, M.; Wilhelm, M.; et al. Exercise intensity assessment and prescription in cardiovascular rehabilitation and beyond: Why and how: A position statement from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. *Eur. J. Prev. Cardiol.* 2022, 29, 230–245. [CrossRef]

51. Ulus, Y.; Durmus, D.; Akyol, Y.; Terzi, Y.; Bilgici, A.; Kuru, O. Reliability and validity of the Turkish version of the Falls Efficacy Scale International (FES-I) in community-dwelling older persons. *Arch. Gerontol. Geriatr.* 2012, 54, 429–433. [CrossRef]

52. Moreira Bde, S.; Dos Anjos, D.M.; Pereira, D.S.; Sampaio, R.F.; Pereira, L.S.; Dias, R.C.; Kirkwood, R.N. The geriatric depression scale and the timed up and go test predict fear of falling in community-dwelling elderly women with type 2 diabetes mellitus: A cross-sectional study. *BMC Geriatr.* 2016, 16, 56. [CrossRef] [PubMed]

53. Faria-Fortini, I.; Polese, J.C.; Faria, C.; Sciani, A.A.; Nascimento, L.R.; Teixeira-Salmela, L.F. Fall Efficacy Scale-International cut-off score discriminates fallers and non-fallers individuals who have had stroke. *J. Bodyw. Mov. Ther.* 2021, 26, 167–173. [CrossRef] [PubMed]